The American Academy of Neurology and American Headache Society released an updated migraine prevention guideline for adults, replacing the 2012 recommendations and reflecting evidence through June 2024.
Criteria for initiating therapy
Clinicians are advised to tell every migraine patient that effective prevention exists for frequent attacks (Level B). The guideline recommends offering treatment to those with four or more migraine days per month, or four or more moderate‑to‑severe headache days, to lower attack frequency (Level B). It also calls for therapy when migraine‑related disability is substantial, regardless of day count.
Patients with chronic migraine—defined as headaches on at least 15 days per month for more than three months, with migraine features on eight of those days—receive the same recommendation framework as episodic sufferers.
How to pick a medication
No single drug has proved clearly superior for efficacy. The panel suggests comparing options across four properties: evidence strength, tolerability, long‑term safety, and cost. For patients prioritizing efficacy, the guideline lists several high‑confidence choices for episodic migraine, including atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, propranolol, topiramate, and valproate.
In chronic migraine, the same CGRP‑targeting agents appear alongside onabotulinumtoxinA, topiramate, and valproate. When tolerability is the main concern, the list narrows to the CGRP monoclonal antibodies and atogepant, which tend to have fewer side effects.
For long‑term safety, clinicians may lean toward older, widely used drugs such as propranolol for episodic cases and onabotulinumtoxinA or topiramate for chronic disease. Cost considerations also influence selection, especially when insurance formularies limit options.
Related: Combined Risk Factors Linked to Late Parkinson Disease
Less‑studied options—amitriptyline, flunarizine, metoprolol, pizotifen, rimegepant, and telmisartan—remain viable for patients who do not respond to higher‑confidence agents.
Comparing this update to the 2012 version shows a marked shift toward newer CGRP‑targeted therapies, which were unavailable a decade ago. While the older guideline focused largely on beta‑blockers and antiepileptics, the current document reflects a broader pharmacologic toolbox, mirroring the rapid expansion of migraine research over the past few years.
Special populations and safety considerations
For patients of childbearing potential, the guideline stresses avoiding known teratogens such as divalproex sodium and topiramate unless benefits outweigh risks (Level A). Non‑drug approaches—behavioral therapy, acupuncture, exercise, and trigger management—should be maximized during pregnancy planning.
If medication is unavoidable during pregnancy, options include nifedipine, with metoprolol or propranolol as alternatives, each weighed against potential fetal risks. OnabotulinumtoxinA may be considered for chronic migraine, though data remain limited.
Older adults require assessment for vascular disease, drug interactions, and reduced organ function. Sedating agents like amitriptyline or pizotifen warrant lower starting doses, and clinicians should discuss hypotension risks when prescribing blood‑pressure‑lowering drugs.
Women on valproic acid need counseling about polycystic ovary syndrome risk; those on high‑dose topiramate should be warned that hormonal contraception may be less effective.
Related: FDA Week: New CMT Trial Framework and Brain Injury Medicine Focus
Managing comorbidities and medication overuse
When migraine coexists with hypertension, the guideline notes that single‑drug regimens—enalapril, nifedipine, or telmisartan—can address both conditions. Amitriptyline is suggested for patients also suffering from fibromyalgia.
Patients meeting medication‑overuse criteria should receive preventive therapy, with CGRP monoclonal antibodies, atogepant, onabotulinumtoxinA, or topiramate highlighted as evidence‑based choices.
Monitoring, adjusting, and discontinuing treatment
Clinicians must evaluate drug interactions between preventive and acute migraine medications (Level A). Most agents require an 8‑ to 12‑week trial at a tolerated dose before efficacy is judged; onabotulinumtoxinA injections need a 24‑week observation period (Level B).
If response is inadequate after eight weeks, dose escalation to the maximum tolerated level is advised. Persistent lack of benefit after 12‑24 weeks should prompt shared decision‑making about switching agents.
Patients should keep a headache diary or use tools like HIT‑6 or MIDAS to track frequency, severity, and impact on quality of life. Counsel on common and serious adverse effects must precede prescribing, and ongoing monitoring is required.
When stopping a preventive, clinicians should discuss the modest risk of rebound headache and consider tapering after at least six months of stable control.